In recent years, the role and mechanism of long non-coding RNA (LncRNA) in cardiovascular diseases have received increasing attention. The chemotherapy agent, doxorubicin (DOX), is one of the most effective drugs for various cancers, but its efficacy is limited by its cardiotoxicity. Therefore, further exploration is required for the molecular mechanism of DOX-induced cardiotoxicity.
View Article and Find Full Text PDFBackground: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to self-antigen, autoantibody production, and abnormal immune response. Cuproptosis is a recently reported cell death form correlated with the initiation and development of multiple diseases. This study intended to probe cuproptosis-related molecular clusters in SLE and constructed a predictive model.
View Article and Find Full Text PDFRecombinant human endostatin (rh-endostatin) is an anti-angiogenic drug, which is used for the treatment of advanced non-small-cell lung cancer (NSCLC) and other cancers. However, its side effects, especially the cardiotoxicity with unclear mechanisms limit its wide application in clinical practice. In this study, human cardiomyocyte cell line AC16 and human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) treated with different doses of rh-endostatin were used to analyze its effect on cardiac cell toxicity.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
December 2022
Long non-coding RNA (LncRNA) is a class of non-coding RNA comprising more than 200 nucleotides. Several studies report that LncRNAs are widely involved in biological processes such as DNA methylation, histone modification, and chromatin remodeling. LncRNA interacts with DNA, RNA, and protein molecules thus regulating expression of target genes.
View Article and Find Full Text PDF